Reference | </br>1:The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Suarez-Kelly LP, Kemper GM, Duggan MC, Stiff A, Noel TC, Markowitz J, Luedke EA, Yildiz VO, Yu L, Jaime-Ramirez AC, Karpa V, Zhang X, Carson WE 3rd.Oncotarget. 2016 Dec 6;7(49):81172-81186. doi: 10.18632/oncotarget.12791. PMID: 27783987 Free PMC Article</br>2:Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells. Engür S, Dikmen M, Öztürk Y.Immunopharmacol Immunotoxicol. 2016;38(2):87-97. doi: 10.3109/08923973.2015.1122616. Epub 2015 Dec 15. PMID: 26667773 </br>3:MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA. Wei X, Zhou P, Lin X, Lin Y, Wu S, Diao P, Xie H, Xie K, Tang P.Tumour Biol. 2014 Oct;35(10):10213-21. doi: 10.1007/s13277-014-2333-y. Epub 2014 Jul 17. PMID: 25027405 </br>4:The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Paulus A, Masood A, Miller KC, Khan AN, Akhtar D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K, Chanan-Khan A.Br J Haematol. 2014 Apr;165(1):78-88. doi: 10.1111/bjh.12731. Epub 2014 Jan 27. PMID: 24467634 </br>5:MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models. Gu JJ, Hernandez-Ilizaliturri FJ, Mavis C, Czuczman NM, Deeb G, Gibbs J, Skitzki JJ, Patil R, Czuczman MS.Anticancer Drugs. 2013 Nov;24(10):1030-8. doi: 10.1097/CAD.0000000000000008. PMID: 23995855
|